Katherine Talcott, MD, discusses phase 2 VERONA results showing EYP-1901 plus aflibercept reduced supplemental treatment ...

Ester Carreño, MD, PhD, explains how to tell retinitis pigmentosa from uveitis and why genetic confirmation now matters more.

The first patients have been enrolled in 4SIGHT, a global phase 3 trial comparing a single intravitreal injection of the investigational gene therapy 4D-150 with aflibercept 2 mg ...

Women’s health is coming into sharper focus more often that previously with the recognition that hormones do make a ...

At EURETINA 2026, Arshad Khanani, MD, FASRS, reviews 2-year SPECTRA data on 4D-150 gene therapy for DMO and the phase 3 4SIGHT trial comparing it with aflibercept. At the 26th EURETINA Congress in ...

Serena Salvatore, MD, discusses the retinal laser training gap, persistent laser myths, simulation and practical advice for safer laser at EURETINA 2026. Salvatore is a consultant ophthalmologist and ...

Three studies presented at the 26th EURETINA Congress, taking place at the VIECON – Vienna Congress & Convention Center from ...

Nimesh Patel, MD, urges the FDA to reconsider SYD-101 as pediatric myopia drives earlier retinal damage in US children. In ...

Sharon Fekrat, MD, FACS, FASRS, discusses how retinal imaging fits into the diagnostic picture for CVI, TBI, and ...

Sequencing IOL choice by eye can ease patient decision paralysis.

Lakhanpal said his first goal with a newly diagnosed patient is to confirm the diagnosis and talk about GA in general. He ...

One of the defining features of the Ophthalmology Times and Optometry Times EyeCon 2026, held virtually on September 26, 2026 ...